Status:
UNKNOWN
MSC for Treatment of cGVHD After Allo-HSCT
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Sun Yat-sen University
Army Medical University, China
Conditions:
Chronic Graft-versus-host Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease.
Detailed Description
Allogeneic hematopoietic stem cell transplantation(allo-HSCT) can cure many hematologic diseases. Although great progress has been made in the prevention and treatment of side effects associated with ...
Eligibility Criteria
Inclusion
- A patient age of 18-65 years
- Recipients of allogeneic hematopoietic stem cell transplantation Patients with moderate/ severe cGVHD without systemic treatment
- Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
Exclusion
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- Primary disease relapse
- Expected lifetime less than 3 months
- Patients with any conditions not suitable for the trial (investigators' decision)
Key Trial Info
Start Date :
January 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2023
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT04692376
Start Date
January 10 2021
End Date
June 30 2023
Last Update
December 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515